HK53496A - Antiviral use of compositions comprising efas and interferon - Google Patents

Antiviral use of compositions comprising efas and interferon

Info

Publication number
HK53496A
HK53496A HK53496A HK53496A HK53496A HK 53496 A HK53496 A HK 53496A HK 53496 A HK53496 A HK 53496A HK 53496 A HK53496 A HK 53496A HK 53496 A HK53496 A HK 53496A
Authority
HK
Hong Kong
Prior art keywords
gamma
interferons
acid
linolenic acid
acids
Prior art date
Application number
HK53496A
Other languages
English (en)
French (fr)
Inventor
Horrobin Frederick
Original Assignee
Scotia Holdings Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc
Publication of HK53496A publication Critical patent/HK53496A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Claims (3)

  1. Verwendung einer Zusammensetzung, die eine oder mehrere der Gamma-Linolen-Säure, Dihomo-Gamma-Linolen-Säure oder Arachidonsäure und ein oder mehrere Interferone umfaßt für die Herstellung eines Medikamentes zur Verwendung für die Erhöhung der antiviralen Wirkungen von Interferon oder Interferonen.
  2. Verwendung gemäß Anspruch 1, wobei das Medikament in einer Einheitsdosierungsform vorliegt und Interferone alpha, beta oder gamma umfaßt in Mengen, die geeignet sind für die Verabreichung von 500.000 bis 500 Millionen Einheiten/Woche, bevorzugt 2 Millionen bis 50 Millionen Einheiten/Woche, sehr bevorzugt 5 Millionen bis 25 Millionen Einheiten/Woche in unterteilten, täglichen oder 2 bis 5 mal wöchentlichen Dosierungen und das Fettsäuren enthält, jede in Mengen, die zur Verabreichung von 1 mg bis 100 g/täglich geeignet sind, bevorzugt 10 mg bis 10g und sehr bevorzugt 100 mg bis 3 g.
  3. Verwendung gemäß Anspruch 1, wobei das Medikament für die topische Verabreichung ist und Konzentrationen von Interferon(en) enthält, die von 100.000 bis 10 Millionen Einheiten/ml verabreicht werden und Konzentration von Fettsäure (Fettsäuren) von 1 mg bis 300 mg/ml.
HK53496A 1989-08-10 1996-03-28 Antiviral use of compositions comprising efas and interferon HK53496A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898918294A GB8918294D0 (en) 1989-08-10 1989-08-10 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
HK53496A true HK53496A (en) 1996-04-03

Family

ID=10661451

Family Applications (1)

Application Number Title Priority Date Filing Date
HK53496A HK53496A (en) 1989-08-10 1996-03-28 Antiviral use of compositions comprising efas and interferon

Country Status (15)

Country Link
US (1) US5580556A (de)
EP (2) EP0416743B1 (de)
AT (1) ATE123948T1 (de)
AU (1) AU633603B2 (de)
CA (1) CA2022608A1 (de)
DE (1) DE69020267T2 (de)
DK (1) DK0416743T3 (de)
ES (1) ES2073533T3 (de)
GB (1) GB8918294D0 (de)
GR (1) GR3016980T3 (de)
HK (1) HK53496A (de)
IE (1) IE67773B1 (de)
NO (1) NO903509L (de)
NZ (1) NZ234786A (de)
ZA (1) ZA906187B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994392A (en) * 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
GB8920228D0 (en) * 1989-09-07 1989-10-18 Efamol Holdings Fatty acid therapy
US5214062A (en) * 1992-04-08 1993-05-25 Clintec Nutrition Co. Method and composition for treating immune disorders, inflammation and chronic infections
GB9304746D0 (en) * 1993-03-09 1993-04-28 Scotia Holdings Plc Treatment of viral infections
CA2255615C (en) * 1996-05-22 2006-08-29 Neuromedica, Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and docetaxel
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US6225444B1 (en) 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
RU2129011C1 (ru) * 1998-04-09 1999-04-20 Григорян Седа Суреновна Способ интерферониндуцирующей или интерферонактивированной терапии и средство для его осуществления
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
US6426367B1 (en) * 1999-09-09 2002-07-30 Efa Sciences Llc Methods for selectively occluding blood supplies to neoplasias
RU2222548C2 (ru) * 2000-07-21 2004-01-27 Зао "Ниармедик Плюс" Применение производного целлюлозы и госсипола в качестве радиопротекторного, противоинфекционного и потенциирующего средства, усовершенствованный способ его получения и фармацевтическая композиция на его основе
JP2005500988A (ja) 2001-03-23 2005-01-13 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド 脂肪族アミン薬物複合体
ATE556706T1 (de) 2001-03-23 2012-05-15 Luitpold Pharm Inc Fettalkohol-arzneimittel-konjugate
RU2238122C1 (ru) * 2003-01-20 2004-10-20 Ооо "Ниармедик Плюс" Противоинфекционный фармацевтический препарат
CA2436650A1 (en) 2003-08-06 2005-02-06 Naturia Inc. Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses
RU2270708C1 (ru) * 2004-05-26 2006-02-27 Ооо "Ниармедик Плюс" Натриевая соль сополимера карбоксиметилцеллюлозы и госсипола, фармацевтическая композиция и способ профилактики или лечения вирусных заболеваний
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
US10471131B2 (en) 2012-01-19 2019-11-12 Hybrid Medical, Llc Topical therapeutic formulations
EP2804606B1 (de) 2012-01-19 2017-06-28 Hybrid Medical, LLC Topische therapeutische formulierungen
SG10201912145VA (en) 2014-06-04 2020-02-27 Dignity Sciences Ltd Pharmaceutical compositions comprising dgla and use of same
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0004770B1 (de) * 1978-04-11 1984-06-13 Efamol Limited Pharmazeutische und diätetische Zusammensetzung mit Gehalt an Gamma-Linolensäuren
US4513008A (en) * 1982-07-30 1985-04-23 The Vinoxen Company, Inc. Virucidal compositions and therapy
EP0106571A3 (de) * 1982-09-22 1984-07-25 Sentrachem Limited Prophylaktische Substanz oder Komposition
GB8319073D0 (en) * 1983-07-14 1983-08-17 Efamol Ltd Fatty acid compositions
GB8507058D0 (en) * 1985-03-19 1985-04-24 Efamol Ltd Pharmaceutical & dietary compositions
US5225441A (en) * 1987-06-18 1993-07-06 Block Drug Company, Inc. Treatment of periodontal disease
CA1338683C (en) * 1988-09-13 1996-10-29 Efamol Holdings Plc Fatty acid therapy and compositions

Also Published As

Publication number Publication date
IE67773B1 (en) 1996-04-17
ES2073533T3 (es) 1995-08-16
DE69020267D1 (de) 1995-07-27
US5580556A (en) 1996-12-03
EP0416743A1 (de) 1991-03-13
DE69020267T2 (de) 1996-01-25
EP0678299A3 (de) 1998-11-04
GR3016980T3 (en) 1995-11-30
CA2022608A1 (en) 1991-02-11
DK0416743T3 (da) 1995-08-14
GB8918294D0 (en) 1989-09-20
AU6017890A (en) 1991-02-14
EP0678299A2 (de) 1995-10-25
AU633603B2 (en) 1993-02-04
IE902774A1 (en) 1991-02-27
NO903509L (no) 1991-02-11
NZ234786A (en) 1997-06-24
NO903509D0 (no) 1990-08-09
EP0416743B1 (de) 1995-06-21
ZA906187B (en) 1991-06-26
ATE123948T1 (de) 1995-07-15

Similar Documents

Publication Publication Date Title
EP0416743B1 (de) Antiviral use of compositions comprising EFAs and Interferon
EP0364094B1 (de) Verwendung von Fettsäuren zur Behandlung von myalgischer Enzephalomyelitis
EP0440341B1 (de) Zusammensetzungen essentieller Fettsäuren und Therapie
EP0222483B1 (de) Verwendung von gamma-Linolensäure und verwandten Verbindungen zur Herstellung eubnes Arzneimittels zur Behandlung von Endometriose
US4970076A (en) Fatty acid composition
EP0132089B1 (de) Fettsäure-Zusammensetzungen
EP0524796B1 (de) Verwendung von essentiellen Fettsäuren zur Herstellung eines Arzneimittels zur Behandlung von AIDS
US4965075A (en) Methods of increasing 1-series PGs in the body
IE903221A1 (en) Fatty acid therapy
EP0409559B1 (de) Pharmazeutische Verwendung von Fettsäuren
JPH0399011A (ja) 医薬組成物

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)